Sunday, July 05, 2020 11:57:57 AM
I just finished watching the interview replay.
I must say NP was thorough, open, fervent in his belief of the product.
I sensed a strong degree of HONESTY.
Several of the questioned asked were direct and important; some of which I would have asked myself. His answers were complete and comprehensive.
I liked the guy and have more trust in him now than before.
Time is the operative word now. Time is what they'll need.But if product can be proven to do 25% of what the company strongly believes it can, it can be a huge winner.
So where am I now. I believe it is worthwhile to hold some shares in the company but hold back going overboard until all is shown to be proven or close to it.
I will continue to use T/A as respects market judgment. Charts and trends do not bend to Q&A sessions. The Trends and its Indicators are exactly what the market is thinking as shown on a chart.
So at some point soon I'll be in again and ready to Hold until proven wrong.Or, I will add pecking away.
Know this: You won't see me going over the top with "beyond rational belief expectations". I'll leave that to fantasy land pipe dreamers.
I must say NP was thorough, open, fervent in his belief of the product.
I sensed a strong degree of HONESTY.
Several of the questioned asked were direct and important; some of which I would have asked myself. His answers were complete and comprehensive.
I liked the guy and have more trust in him now than before.
Time is the operative word now. Time is what they'll need.But if product can be proven to do 25% of what the company strongly believes it can, it can be a huge winner.
So where am I now. I believe it is worthwhile to hold some shares in the company but hold back going overboard until all is shown to be proven or close to it.
I will continue to use T/A as respects market judgment. Charts and trends do not bend to Q&A sessions. The Trends and its Indicators are exactly what the market is thinking as shown on a chart.
So at some point soon I'll be in again and ready to Hold until proven wrong.Or, I will add pecking away.
Know this: You won't see me going over the top with "beyond rational belief expectations". I'll leave that to fantasy land pipe dreamers.
Recent CYDY News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/02/2025 10:15:21 PM
